CTOs on the Move

Forest Laboratories

www.frx.com

 
Forest Laboratories is a pharmaceutical company headquartered in New York City, US. The company's research and development spending has grown rapidly in recent years and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending. Forest Laboratories is also known for licensing European pharmaceuticals for sale in the United States.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.frx.com
  • 909 3rd Ave
    New York, NY USA 10022
  • Phone: 212.421.7850

Executives

Name Title Contact Details

Similar Companies

Envivo

Envivo is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Union Center Pharmacy

Union Center Pharmacy is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Innoviant

Innoviant, Inc. is a Wausau, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Detroit Wayne Mental Health Authority

DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.